Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Conditions:   Advanced Solid Tumors;   NSCLC;   Bladder Cancer;   HNSCC;   Renal Cancer;   Melanoma;   Anal Cancer;   Colorectal Cancer;   Cholangiocarcinoma;   Gastric Cancer;   Hepatocellular Carcinoma Interventions:   Drug: Continue PD-1/PD-L1 Inhibitors treatment;   Other: Discontinue PD-1/PD-L1-1 inhibitor Sponsor:   Antoinette J Wozniak Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials